Literature DB >> 20437455

Analysis of interval-censored disease progression data via multi-state models under a nonignorable inspection process.

Baojiang Chen1, Grace Y Yi, Richard J Cook.   

Abstract

Irreversible multi-state models provide a convenient framework for characterizing disease processes that arise when the states represent the degree of organ or tissue damage incurred by a progressive disease. In many settings, however, individuals are only observed at periodic clinic visits and so the precise times of the transitions are not observed. If the life history and observation processes are not independent, the observation process contains information about the life history process, and more importantly, likelihoods based on the disease process alone are invalid. With interval-censored failure time data, joint models are nonidentifiable and data analysts must rely on sensitivity analyses to assess the effect of the dependent observation times. This paper is concerned, however, with the analysis of data from progressive multi-state disease processes in which individuals are scheduled to be seen at periodic pre-scheduled assessment times. We cast the problem in the framework used for incomplete longitudinal data problems. Maximum likelihood estimation via an EM algorithm is advocated for parameter estimation. Simulation studies demonstrate that the proposed method works well under a variety of situations. Data from a cohort of patients with psoriatic arthritis are analyzed for illustration. Copyright 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2010        PMID: 20437455     DOI: 10.1002/sim.3804

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  A hidden Markov model approach to analyze longitudinal ternary outcomes when some observed states are possibly misclassified.

Authors:  Julia S Benoit; Wenyaw Chan; Sheng Luo; Hung-Wen Yeh; Rachelle Doody
Journal:  Stat Med       Date:  2016-01-18       Impact factor: 2.373

2.  Analysis of the bypass angioplasty revascularization investigation trial using a multistate model of clinical outcomes.

Authors:  Xiao Zhang; Quanlin Li; Andre Rogatko; Mourad Tighiouart; Regina M Hardison; Maria Mori Brooks; Sheryl F Kelsey; Sanjay Kaul; C Noel Bairey Merz
Journal:  Am J Cardiol       Date:  2015-02-02       Impact factor: 2.778

3.  Non-homogeneous Markov process models with informative observations with an application to Alzheimer's disease.

Authors:  Baojiang Chen; Xiao-Hua Zhou
Journal:  Biom J       Date:  2011-04-14       Impact factor: 2.207

4.  Marginal methods for clustered longitudinal binary data with incomplete covariates.

Authors:  Baojiang Chen; Grace Y Yi; Richard J Cook; Xiao-Hua Zhou
Journal:  J Stat Plan Inference       Date:  2012-10       Impact factor: 1.111

5.  A joint model for multistate disease processes and random informative observation times, with applications to electronic medical records data.

Authors:  Jane M Lange; Rebecca A Hubbard; Lurdes Y T Inoue; Vladimir N Minin
Journal:  Biometrics       Date:  2014-10-15       Impact factor: 2.571

6.  A Correlated Random Effects Model for Non-homogeneous Markov Processes with Nonignorable Missingness.

Authors:  Baojiang Chen; Xiao-Hua Zhou
Journal:  J Multivar Anal       Date:  2013-05       Impact factor: 1.473

7.  Predictors of Durability of Radiological Response in Patients With Small Bowel Crohn's Disease.

Authors:  Parakkal Deepak; Joel G Fletcher; Jeff L Fidler; John M Barlow; Shannon P Sheedy; Amy B Kolbe; William S Harmsen; Terry Therneau; Stephanie L Hansel; Brenda D Becker; Edward V Loftus; David H Bruining
Journal:  Inflamm Bowel Dis       Date:  2018-07-12       Impact factor: 5.325

8.  Multi-state modelling of repeated hospitalisation and death in patients with heart failure: The use of large administrative databases in clinical epidemiology.

Authors:  Francesca Ieva; Christopher H Jackson; Linda D Sharples
Journal:  Stat Methods Med Res       Date:  2015-03-26       Impact factor: 3.021

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.